1st Quarter 2024 Results[1]

1st Quarter 2024 Sales

$21.4B Worldwide increased ▲ **2.3%**

Excluding acquisitions / divestitures on an operational basis: Worldwide increased ▲ **7.7%*,2**

Diluted earnings per share **$2.20**

Adjusted diluted earnings per share*

$2.71 Increased ▲ **12.4%**





"Johnson & Johnson's solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline. Our impact across the full spectrum of healthcare is unique in our industry, and the milestones achieved this quarter reinforce our position as an innovation powerhouse."

Joaquin Duato
Chairman & Chief Executive Officer
Johnson & Johnson

$13.6 billion Worldwide Innovative Medicine sales

Innovative Medicine worldwide reported sales increased 6.9%[2] or 8.3%[2] operationally[3]. Primary operational drivers:

DARZALEX® (daratumumab) injection for intravenous infusion 100 mg/5 mL, 400 mg/20 mL
Tremfya® (guselkumab)
Erleada® (apalutamide) 60 mg tablets 240 mg tablet
Uptravi® selexipag tablets 200-1600 mcg
Spravato™ (esketamine) CII nasal spray
Opsumit® macitentan
CARVYKTI® (ciltacabtagene autoleucel) Suspension for IV infusion
TECVAYLI® (teclistamab-cqyv) Injection for subcutaneous use 10 mg/mL and 90 mg/mL

$7.8 billion Worldwide MedTech sales

MedTech worldwide reported sales increased 4.5% or 6.3% operationally[3]. Primary operational drivers:

- Electrophysiology
- Wound Closure
- Abiomed
- Knees
- Hips
- Biosurgery

For full financial data, and non-GAAP reconciliations, and cautionary statements, please refer to Johnson & Johnson's earnings release issued April 16, 2024, available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

[1] Results have been recast to reflect the continuing operations of Johnson & Johnson.

[2] Excluding COVID-19 Vaccine.

[3] Non-GAAP measure; excludes the impact of translational currency.

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on April 16, 2024, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.

Johnson&Johnson